A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

NCT04709276 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Prostate Neuroendocrine Carcinoma
Metastatic Prostate Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Carboplatin
DRUG: Cabazitaxel

Sponsor

Andrew J. Armstrong, MD

Collaborators

[object Object]